Belgian biopharmaceutical company Mithra Pharmaceuticals SA (Euronext Brussels:MITRA) reported on Thursday that it has received feedback from the US Food and Drug Administration (FDA) regarding its marketing authorisation filing for DONESTA, an oestrogen-based therapy for vasomotor symptoms of menopause.
This follows an earlier agreement in principle with the FDA to conduct additional endometrial data analyses in order to address variations in endometrial biopsy diagnoses and optimise market potential. The formal New Drug Application (NDA) submission is now planned for Q4 2024 to allow for the time required to perform these additional analyses pursuant to FDA guidance.
Due to the delay, complementary data will be submitted for both the FDA and the European Medicines Agency (EMA) within the same time frame.
Welcoming the FDA's feedback, Mithra's chief scientific officer Graham Dixon said: "Estetrol's action on the uterine lining is well understood and expected. These additional data inform our research on other promising applications of E4 in women's health.
"In fact, this effect can potentially be used as a treatment to enhance fertility for women who are undergoing IVF, for example. We have begun research to explore an estetrol-based solution for this market."
Mithra added that it continues to actively seek a commercialisation partner for the US market and has received positive interest from several potential candidates.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment